COVID-19-related delays of botulinum toxin injections have a negative impact on the quality of life of patients with dystonia and spasticity: a single-center ambulatory care study.
Yvonne TeuschlChristian BancherMichael BraininAlexandra DachenhausenKarl MatzMichaela M PinterPublished in: Journal of neural transmission (Vienna, Austria : 1996) (2021)
COVID-19-related delays in BoNT-A injections illustrate the importance of this therapy for symptom relief, functional outcome, and QoL in patients suffering from involuntary muscle hyperactivity. BoNT-A therapy is essential and has to be guaranteed even in circumstances such as the COVID-19 pandemic.
Keyphrases
- botulinum toxin
- coronavirus disease
- sars cov
- end stage renal disease
- ejection fraction
- healthcare
- chronic kidney disease
- newly diagnosed
- palliative care
- blood pressure
- ultrasound guided
- skeletal muscle
- prognostic factors
- peritoneal dialysis
- platelet rich plasma
- stem cells
- quality improvement
- deep brain stimulation
- cell therapy
- upper limb
- drug induced
- cerebral palsy